These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 17374831

  • 41. Stocks' study renews concerns over insider trading on oncology drugs.
    Goozner M.
    J Natl Cancer Inst; 2011 Nov 16; 103(22):1652-5. PubMed ID: 22025626
    [No Abstract] [Full Text] [Related]

  • 42. Raising the bar of efficacy for drug approval requires an understanding of patient diversity.
    Berger ML, Eck S, Ruberg SJ.
    J Clin Oncol; 2010 Jul 10; 28(20):e343-4; author reply e345. PubMed ID: 20458030
    [No Abstract] [Full Text] [Related]

  • 43. Drug development research: the process.
    Sataloff RT.
    Ear Nose Throat J; 2008 Aug 10; 87(8):420-2. PubMed ID: 18712686
    [No Abstract] [Full Text] [Related]

  • 44. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.
    Woosley RL, Myers RT, Goodsaid F.
    Clin Pharmacol Ther; 2010 May 10; 87(5):530-3. PubMed ID: 20407457
    [Abstract] [Full Text] [Related]

  • 45. Biotechnology on the RAC--FDA/NIH regulation of human gene therapy.
    Rainsbury JM.
    Food Drug Law J; 2000 May 10; 55(4):575-600. PubMed ID: 12025851
    [No Abstract] [Full Text] [Related]

  • 46. Accelerated approval regulations may need overhaul, panel suggests.
    Finkelstein JB.
    J Natl Cancer Inst; 2005 Dec 21; 97(24):1802-4. PubMed ID: 16368938
    [No Abstract] [Full Text] [Related]

  • 47. The process of drug development.
    Burgess G.
    Surviv News (Atlanta Ga); 2002 Mar 21; ():18. PubMed ID: 11966191
    [No Abstract] [Full Text] [Related]

  • 48. US health agencies at odds over trial deaths.
    Macilwain C.
    Nature; 1994 Jun 09; 369(6480):433. PubMed ID: 8202125
    [No Abstract] [Full Text] [Related]

  • 49. Concern grows over reaction to deaths in clinical trials.
    Macilwain C.
    Nature; 1994 May 26; 369(6478):268. PubMed ID: 8183354
    [No Abstract] [Full Text] [Related]

  • 50. How are drugs approved? Part 3. The stages of drug development.
    Howland RH.
    J Psychosoc Nurs Ment Health Serv; 2008 Mar 26; 46(3):17-20. PubMed ID: 18416270
    [Abstract] [Full Text] [Related]

  • 51. FDA tightens human oversight.
    Dove A.
    Nat Med; 2001 Jun 26; 7(6):646. PubMed ID: 11385485
    [No Abstract] [Full Text] [Related]

  • 52. Managed care outlook. Oncologists: FDA needs to speed up approval of cancer-fighting drugs.
    Manag Care; 2002 Jun 26; 11(6):56. PubMed ID: 12098877
    [No Abstract] [Full Text] [Related]

  • 53. Finding value in the U.S. Food and Drug Administration's Fast Track program.
    Reichert JM, Rochon SL, Zhang BD.
    Drug News Perspect; 2009 Jun 26; 22(1):53-8. PubMed ID: 19209299
    [Abstract] [Full Text] [Related]

  • 54. Obstacles at the FDA?
    Delap RJ.
    Sci Am; 1997 Jan 26; 276(1):8. PubMed ID: 8972611
    [No Abstract] [Full Text] [Related]

  • 55. The ODAC chronicles: part 1. My first ODAC experience.
    Grillo-López AJ.
    Expert Rev Anticancer Ther; 2004 Oct 26; 4(5):709-12. PubMed ID: 15485306
    [No Abstract] [Full Text] [Related]

  • 56. Strong medicine.
    Wadman M.
    Nat Med; 2005 May 26; 11(5):465-6. PubMed ID: 15875044
    [No Abstract] [Full Text] [Related]

  • 57. Translation of cancer immunotherapies.
    Mulé JJ, Weber JS.
    Nat Med; 2004 Nov 26; 10(11):1153; author reply 1153-4. PubMed ID: 15516900
    [No Abstract] [Full Text] [Related]

  • 58. Omacetaxine: the FDA decision.
    Berman E.
    Clin Adv Hematol Oncol; 2011 Jan 26; 9(1):57-8. PubMed ID: 21326148
    [No Abstract] [Full Text] [Related]

  • 59. FDA approves sorafenib for patients with inoperable liver cancer.
    Lang L.
    Gastroenterology; 2008 Feb 26; 134(2):379. PubMed ID: 18242200
    [No Abstract] [Full Text] [Related]

  • 60. Orphan products activities of the National Institutes of Health.
    Schepartz SA.
    Prog Clin Biol Res; 1983 Feb 26; 127():173-86. PubMed ID: 6889399
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.